Result of General Meeting

Verici Dx plc

("Verici Dx" or the "Company")

Result of General Meeting

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the General Meeting ("GM") held earlier today, all resolutions, as set out in the GM notice published on 5 June 2026, were duly passed on a poll. Resolution 1 was passed as an ordinary resolution and resolution 2 was passed as a special resolution.

The voting results of the GM were as follows:

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the 700,000,000 Placing Shares and 53,345,832 WRAP Retail Offer Shares ("Admission"). It is expected that Admission will become effective and that trading will commence in the Placing Shares and WRAP Retail Offer Shares at 8.00 a.m. on 23 June 2026. Additionally, an adviser to the Company has agreed to have issued to it 20,571,428 new Ordinary Shares (the "Adviser Shares") at the Issue Price in lieu of fees that would otherwise have been owed to it. It is expected that Admission of the Adviser Shares will also become effective at 8.00 a.m. on 23 June 2026 and trading in such shares will commence at such time.

Following Admission, the total issued share capital of the Company will consist of 2,287,311,387 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 2,287,311,387. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The new Ordinary Shares will be fully paid and will rank pari passu in all respects with each other and with the existing Ordinary Shares of the Company.

Capitalised terms not defined have the same meaning as given to them in the Company's Circular dated 5 June 2026.

Enquires:

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.